Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer

[1]  E. Kuijper,et al.  Plasmid-mediated metronidazole resistance in Clostridioides difficile , 2019, Nature Communications.

[2]  L. Munoz-Price,et al.  Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Dupont,et al.  Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule , 2019, mSystems.

[4]  Soo‐Ki Kim,et al.  Probiotic supplements might not be universally-effective and safe: A review. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  D. Gerding,et al.  Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection with Greater Severity and Higher Recurrence Rates. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Fan,et al.  Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation , 2018, Front. Microbiol..

[7]  B. Helmink,et al.  Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.

[8]  F. Qeadan,et al.  Zolpidem Use Is a Potential Risk Factor for Clostridium difficile Colitis in Hospitalized Patients: A Large Case Control Study , 2018, American Journal of Gastroenterology.

[9]  David H. Chong,et al.  Rapid gastrointestinal loss of Clostridial Clusters IV and XIVa in the ICU associates with an expansion of gut pathogens , 2018, PloS one.

[10]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Perez,et al.  Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment , 2017, Medical mycology case reports.

[12]  R. Madan,et al.  Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection. , 2017, Anaerobe.

[13]  F. Månsson,et al.  The Association between GABA-Modulators and Clostridium difficile Infection – A Matched Retrospective Case-Control Study , 2017, PloS one.

[14]  Jennifer Beardsley,et al.  Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. , 2017, The Cochrane database of systematic reviews.

[15]  L. Dembry,et al.  Epidemiology of Clostridium difficile infection in hospitalized oncology patients. , 2016, American journal of infection control.

[16]  Ben Nichols,et al.  Distributed under Creative Commons Cc-by 4.0 Vsearch: a Versatile Open Source Tool for Metagenomics , 2022 .

[17]  Peter T. McKenney,et al.  Clostridium difficile colitis: pathogenesis and host defence , 2016, Nature Reviews Microbiology.

[18]  K. Garey,et al.  Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. , 2016, The Journal of hospital infection.

[19]  A. Wanger,et al.  Carbapenem-resistant Lactobacillus intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption , 2016, Infection.

[20]  Dustin L. Stwalley,et al.  The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases , 2016, BMC Infectious Diseases.

[21]  V. Young,et al.  Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine , 2016, mSphere.

[22]  L. Rybicki,et al.  Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients , 2016, Bone Marrow Transplantation.

[23]  V. Young,et al.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. , 2015, Annual review of microbiology.

[24]  L. Kitanovski,et al.  Bifidobacterium breve Sepsis in Child with High-Risk Acute Lymphoblastic Leukemia , 2015, Emerging infectious diseases.

[25]  A. Levy,et al.  Incidence and Costs of Clostridium difficile Infections in Canada , 2015, Open forum infectious diseases.

[26]  S. Rodríguez,et al.  Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  K. Garey,et al.  Healthcare Resource Utilization for Recurrent Clostridium difficile Infection in a Large University Hospital in Houston, Texas , 2014, PloS one.

[28]  R. Britton,et al.  Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. , 2014, Gastroenterology.

[29]  Yeul-Hong Kim,et al.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy , 2014, Supportive Care in Cancer.

[30]  V. Mai,et al.  Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea , 2013, Journal of Clinical Microbiology.

[31]  Susan Holmes,et al.  phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data , 2013, PloS one.

[32]  David N. Fisman,et al.  Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection , 2013, Antimicrobial Agents and Chemotherapy.

[33]  Areej Khan,et al.  The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. , 2012, Recent patents on anti-infective drug discovery.

[34]  E. Pamer,et al.  Critical Role for MyD88-Mediated Neutrophil Recruitment during Clostridium difficile Colitis , 2012, Infection and Immunity.

[35]  William A. Walters,et al.  Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms , 2012, The ISME Journal.

[36]  D. Slymen,et al.  Risk factors associated with complications and mortality in patients with Clostridium difficile infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[38]  Martin Hartmann,et al.  Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.

[39]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[40]  E. Kuijper,et al.  Emergence of reduced susceptibility to metronidazole in Clostridium difficile. , 2008, The Journal of antimicrobial chemotherapy.

[41]  R. Knight,et al.  Quantitative and Qualitative β Diversity Measures Lead to Different Insights into Factors That Structure Microbial Communities , 2007, Applied and Environmental Microbiology.

[42]  S. Routhier,et al.  Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  R. Knight,et al.  UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.

[44]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[45]  G. Macfarlane,et al.  Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. , 2002, Journal of medical microbiology.

[46]  T. Sauerbruch,et al.  Clostridium difficile infection in patients with neutropenia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  D. Gerding,et al.  Clostridium difficile--associated diarrhea. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  A. Glatt,et al.  Clostridium difficile infection associated with antineoplastic chemotherapy: a review. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  S. Hirschman,et al.  Clostridium difficile diarrhea induced by cancer chemotherapy. , 1992, Archives of internal medicine.

[50]  R. Warren,et al.  ATYPICAL CLOSTRIDIUM DIFFICILE COLITIS IN NEUTROPENIC PATIENTS , 1982, The Lancet.